Should I buy or sell MacroGenics stock right now?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MGNX shares. View MGNX analyst ratings or view top-rated stocks .

What is MacroGenics' stock price target for 2024?

8 analysts have issued twelve-month price objectives for MacroGenics' stock. Their MGNX share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 5.6% from the stock's current price. View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts .

How have MGNX shares performed in 2024?

MacroGenics' stock was trading at $9.62 at the beginning of 2024. Since then, MGNX stock has increased by 67.4% and is now trading at $16.10. View the best growth stocks for 2024 here .

When is MacroGenics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our MGNX earnings forecast .

How were MacroGenics' earnings last quarter?

MacroGenics, Inc. (NASDAQ:MGNX) issued its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.49. The biopharmaceutical company had revenue of $10.72 million for the quarter, compared to analyst estimates of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative trailing twelve-month return on equity of 88.49%. During the same period in the prior year, the firm posted $0.21 earnings per share.

What ETFs hold MacroGenics' stock?

ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Genomics Immunology and Healthcare ETF (IDNA) . iShares Micro-Cap ETF (IWC) .

What is Scott Koenig's approval rating as MacroGenics' CEO?

12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com . Scott Koenig has an approval rating of 89% among the company's employees.

What other stocks do shareholders of MacroGenics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV) , Exelixis (EXEL) , Gilead Sciences (GILD) , NVIDIA (NVDA) , Micron Technology (MU) , Sangamo Therapeutics (SGMO) , Sorrento Therapeutics (SRNE) , Intra-Cellular Therapies (ITCI) , TG Therapeutics (TGTX) and Bausch Health Companies (BHC) .

Who are MacroGenics' major shareholders?

MacroGenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.09%) and Sound Income Strategies LLC (0.01%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels , Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel . View institutional ownership trends .

How do I buy shares of MacroGenics?

Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:MGNX

MacroGenics (MGNX) Stock Price, News & Analysis

→ Bitcoin Rockets To Record High But Buy THIS Instead (From Paradigm Press) (Ad)

Free MGNX Stock Alerts

$16.10

-0.58 (-3.48%)

(As of 04/17/2024 ET)

Compare

Today's Range: $16.00
▼
$16.83
50-Day Range: $13.31
▼
$21.47
52-Week Range: $4.29
▼
$21.88

Volume: 952,955 shs
Average Volume: 1.39 million shs
Market Capitalization: $1.01 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $17.00

Get MacroGenics alerts:

MacroGenics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.88 Rating Score
Upside/Downside: 5.6% Upside
$17.00 Price Target
Short Interest: Bearish
11.01% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.61
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: Selling Shares
$1.44 M Sold Last Quarter
Proj. Earnings Growth: Growing
From ($2.70) to ($1.54) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.86 out of 5 stars

Medical Sector

381st out of 913 stocks

Pharmaceutical Preparations Industry

157th out of 396 stocks

2.4

Analyst's Opinion

Consensus Rating
MacroGenics has received a consensus rating of Moderate Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
MacroGenics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
11.01% of the float of MacroGenics has been sold short.
Short Interest Ratio / Days to Cover
MacroGenics has a short interest ratio ("days to cover") of 4.1.
Change versus previous month
Short interest in MacroGenics has recently increased by 15.18%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
MacroGenics does not currently pay a dividend.
Dividend Growth
MacroGenics does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
MacroGenics has received a 66.61% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Monoclonal antibodies" and "Clinical research services for cancer" products. See details.
Environmental Sustainability
The Environmental Impact score for MacroGenics is -1.61.

1.3

News and Social Media Coverage

News Sentiment
MacroGenics has a news sentiment score of 0.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
Search Interest
Only 4 people have searched for MGNX on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.
MarketBeat Follows
Only 4 people have added MacroGenics to their MarketBeat watchlist in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, MacroGenics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,436,380.00 in company stock.
Percentage Held by Insiders
Only 10.00% of the stock of MacroGenics is held by insiders.
Percentage Held by Institutions
96.89% of the stock of MacroGenics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for MacroGenics are expected to grow in the coming year, from ($2.70) to ($1.54) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of MacroGenics is -100.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of MacroGenics is -100.63, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
MacroGenics has a P/B Ratio of 6.54. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Market Moving Trends

Top 5 AI Stocks to Buy for 2024

5 Best AI Stocks to Invest In Investors are getting very rich in AI stocks right now. Wall Street legend is giving away the name and ticker of the little-known AI stock Wall Street is currently buying hand-over-fist.

Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"

About MacroGenics Stock (NASDAQ:MGNX)

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.

MGNX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

MGNX Stock News Headlines

April 9, 2024 | insidertrades.com

Jeffrey Stuart Peters Sells 51,395 Shares of MacroGenics, Inc. (NASDAQ:MGNX) Stock

April 10, 2024 | markets.businessinsider.com

Buy Rating Affirmed for MacroGenics with Promising Vobra Duo Data and Anticipated 2024 Clarifications

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 10, 2024 | americanbankingnews.com

MacroGenics (NASDAQ:MGNX) Upgraded to "Buy" by TD Cowen

April 10, 2024 | nasdaq.com

Validea Detailed Fundamental Analysis - MGNX

April 9, 2024 | americanbankingnews.com

MacroGenics, Inc. (NASDAQ:MGNX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

April 6, 2024 | uk.investing.com

MacroGenics Analyst Impressed By Improved Safety Profile From Prostate Cancer Candidate

April 5, 2024 | seekingalpha.com

MacroGenics: Positive Safety Update Leads To Two Major Inflection Points In 2024

April 18, 2024 | Paradigm Press (Ad)

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

April 4, 2024 | markets.businessinsider.com

Buy Rating Affirmed for MacroGenics on Strong Safety Profile and Anticipated Efficacy Data

April 4, 2024 | markets.businessinsider.com

The Latest Analyst Ratings For Macrogenics

April 4, 2024 | markets.businessinsider.com

Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session

April 4, 2024 | msn.com

MacroGenics gains after mid-stage data for antibody drug conjugate

April 4, 2024 | markets.businessinsider.com

Positive Outlook for MacroGenics: Buy Rating Affirmed Amid Vobra-duo Developments

April 3, 2024 | globenewswire.com

MacroGenics Provides Phase 2 TAMARACK Study Early Interim Safety Data and Plans for Future Disclosures

March 16, 2024 | finance.yahoo.com

MGNX Apr 2024 10.000 put

March 16, 2024 | finance.yahoo.com

MGNX Dec 2024 17.500 put

March 15, 2024 | ca.finance.yahoo.com

MGNX Mar 2024 22.500 put

March 14, 2024 | msn.com

The Potential of MacroGenics’ (NASDAQ:MGNX) Pipeline is Driving the Stock

March 14, 2024 | finance.yahoo.com

MacroGenics, Inc. (NASDAQ:MGNX) Q4 2023 Earnings Call Transcript

March 11, 2024 | realmoney.thestreet.com

MacroGenics price target raised by $6 at JMP Securities, here's why

March 11, 2024 | msn.com

3 Best Stocks to Buy Now, 3/11/2024, According to Top Analysts

March 11, 2024 | realmoney.thestreet.com

MacroGenics price target raised by $12 at Citi, here's why

March 11, 2024 | markets.businessinsider.com

Maintaining Market Outperform for MacroGenics with Increased Confidence in ADC Leadership and Clinical Prospects

March 11, 2024 | markets.businessinsider.com

Buy Rating Affirmed for MacroGenics on Promising Pipeline and Strong Financials

March 10, 2024 | fool.com

MacroGenics (NASDAQ: MGNX)

March 8, 2024 | fool.com

MacroGenics (MGNX) Q4 2023 Earnings Call Transcript

See More Headlines

Receive MGNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MacroGenics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/07/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/14/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:MGNX
CUSIP: N/A
CIK: 1125345
Web: www.macrogenics.com
Phone: (301) 251-5172
Fax: 301-251-5321
Employees: 339
Year Founded: 2000

Price Target and Rating

Average Stock Price Target: $17.00
High Stock Price Target: $24.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +5.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.88
Research Coverage: 8 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.16)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,060,000.00
Net Margins: -15.42%
Pretax Margin: -15.42%
Return on Equity: -88.49%
Return on Assets: -43.12%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.48
Quick Ratio: 4.46

Sales & Book Value

Annual Sales: $58.75 million
Price / Sales: 17.14
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $2.46 per share
Price / Book: 6.54

Miscellaneous

Outstanding Shares: 62,560,000
Free Float: 56,305,000
Market Cap: $1.01 billion
Optionable: Optionable
Beta: 2.09

Social Links

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

Dr. Scott Koenig M.D. (Age 72)
Ph.D., President, CEO & Director
Comp: $1.06M
Mr. James Karrels (Age 57)
Senior VP, CFO & Corporate Secretary
Comp: $626.83k
Mr. Eric Blasius Risser (Age 51)
Chief Operating Officer
Comp: $651.36k
Dr. Thomas M. Spitznagel Ph.D. (Age 57)
Senior Vice President of Technical Operations
Comp: $550.97k
Dr. Ezio Bonvini (Age 70)
Senior VP of Research & Chief Scientific Officer
Comp: $612.21k
Mr. Jeffrey Stuart Peters (Age 53)
Senior VP, General Counsel & Corporate Compliance Officer
Dr. Stephen L. Eck M.D. (Age 69)
Ph.D., Senior VP of Clinical Development & Chief Medical Officer
Comp: $577.62k
Ms. Lynn Cilinski (Age 66)
VP, Controller & Treasurer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MGNX Stock Analysis - Frequently Asked Questions

Should I buy or sell MacroGenics stock right now?: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MacroGenics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" MGNX shares.
View MGNX analyst ratings or view top-rated stocks.
What is MacroGenics' stock price target for 2024?: 8 analysts have issued twelve-month price objectives for MacroGenics' stock. Their MGNX share price targets range from $12.00 to $24.00. On average, they expect the company's share price to reach $17.00 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for MGNX or view top-rated stocks among Wall Street analysts.
How have MGNX shares performed in 2024?: MacroGenics' stock was trading at $9.62 at the beginning of 2024. Since then, MGNX stock has increased by 67.4% and is now trading at $16.10.
View the best growth stocks for 2024 here.
When is MacroGenics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our MGNX earnings forecast.
How were MacroGenics' earnings last quarter?: MacroGenics, Inc. (NASDAQ:MGNX) issued its quarterly earnings data on Thursday, March, 7th. The biopharmaceutical company reported ($0.75) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.49. The biopharmaceutical company had revenue of $10.72 million for the quarter, compared to analyst estimates of $25.70 million. MacroGenics had a negative net margin of 15.42% and a negative trailing twelve-month return on equity of 88.49%. During the same period in the prior year, the firm posted $0.21 earnings per share.
What ETFs hold MacroGenics' stock?: ETFs with the largest weight of MacroGenics (NASDAQ:MGNX) stock in their portfolio include Virtus LifeSci Biotech Clinical Trials ETF (BBC) and iShares Genomics Immunology and Healthcare ETF (IDNA).iShares Micro-Cap ETF (IWC).

What is Scott Koenig's approval rating as MacroGenics' CEO?: 12 employees have rated MacroGenics Chief Executive Officer Scott Koenig on Glassdoor.com. Scott Koenig has an approval rating of 89% among the company's employees.
What other stocks do shareholders of MacroGenics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MacroGenics investors own include AbbVie (ABBV), Exelixis (EXEL), Gilead Sciences (GILD), NVIDIA (NVDA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Sorrento Therapeutics (SRNE), Intra-Cellular Therapies (ITCI), TG Therapeutics (TGTX) and Bausch Health Companies (BHC).
Who are MacroGenics' major shareholders?: MacroGenics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Los Angeles Capital Management LLC (0.09%) and Sound Income Strategies LLC (0.01%). Insiders that own company stock include Edward Hurwitz, Ezio Bonvini, James Karrels, Jeffrey Stuart Peters, Target N V Biotech and Thomas Spitznagel.
View institutional ownership trends.
How do I buy shares of MacroGenics?: Shares of MGNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MGNX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

MacroGenics (MGNX) Stock Price, News & Analysis

MacroGenics MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About MacroGenics Stock (NASDAQ:MGNX)

MGNX Stock Price History

MGNX Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Social Links

Key Executives

Key Competitors

Insiders & Institutions

MGNX Stock Analysis - Frequently Asked Questions

Overall MarketRank^™